The Ray Peat Protocol: Complete 2026 Research Guide
Ray Peat (1936-2022) was an American endocrinologist and biologist who spent five decades developing a systems-level framework for understanding metabolism, hormones, and chronic illness - work he disseminated primarily through newsletters, interviews, and a body of self-published writing that began in the early 1970s and continued through the 2010s. His framework, now commonly referred to as the "bioenergetic model" or the Ray Peat protocol, is built around a single central thesis: metabolism is the master variable governing health, and thyroid hormone - specifically T3 - is the primary regulator of metabolic rate. The protocol pairs T3 optimization with anti-serotonin tooling, pregnenolone, progesterone, methylene blue, and a dietary framework designed to maximize oxidative phosphorylation and minimize metabolic suppression. Despite limited endorsement from mainstream academic endocrinology, the framework has developed a substantial and technically sophisticated research community that continues to generate practical protocols based on Peat's foundational mechanistic arguments. This article reviews the bioenergetic framework in full - its origin, its core compound stack, the controversies it has generated, and how it connects to emerging T3+T2 research.
Research framing. This article reviews the Ray Peat bioenergetic framework from a research-context standpoint. All compounds discussed are sold strictly for laboratory research and not for human consumption. See our /faq#legality page for full terms.
Buy Now →Research Grade · Discreet Worldwide Shipping
Wilson's SR-T3 Combo Kit
Origin and Framework Overview
Ray Peat completed his PhD at the University of Oregon in 1972, where his dissertation examined estrogen's role in cellular aging and oxygen consumption. That foundational work - the observation that estrogen suppresses oxidative metabolism while progesterone supports it - became the seed of a career-long investigation into which hormonal and nutritional factors suppress or support mitochondrial respiration. Peat's central insight, developed and refined across dozens of newsletters distributed from the 1970s through the 2010s, was that most chronic-illness presentations could be traced to a suppressed metabolic rate, and that metabolic rate suppression was the result of a predictable set of hormonal and nutritional inputs: thyroid hormone deficiency (especially at the tissue level, not just on TSH panels), estrogen excess, serotonin excess, excess polyunsaturated fats, and inadequate saturated fat and sugar as fuel substrates.
The bioenergetic framework is not primarily a protocol for specific diseases. It is a framework for metabolic optimization: restore thyroid hormone to a level where body temperature is consistently near 98.6 degrees Fahrenheit (the temperature at which oxidative phosphorylation runs at peak efficiency), reduce serotonin's action at the cellular level, supply the parent steroids pregnenolone and progesterone, use methylene blue to directly support mitochondrial electron transport, and structure the diet around fuels that support oxidative phosphorylation rather than glycolysis and fat storage. The community that formed around Peat's writing attracted researchers, self-experimenters, and clinicians interested in a bottom-up mechanistic model of chronic illness that was distinct from both mainstream endocrinology and conventional naturopathy.
What made Peat's framework enduring was not any single claim but the internal coherence of the model. Each element connects to the others through documented biochemical mechanism. The serotonin argument draws on peer-reviewed literature showing serotonin's role in vasoconstriction, cortisol release, and mitochondrial Complex I inhibition. The T3 argument rests on established thyroid hormone biochemistry. The progesterone argument traces back to Peat's own dissertation-era work and is supported by a substantial literature on progesterone's neurosteroid function. The dietary arguments engage with published work on lipid peroxidation, substrate utilization, and insulin sensitivity. Whether any individual element is correct is a separate question from whether the framework is mechanistically coherent - and on coherence, the bioenergetic model is unusually strong for its position outside the mainstream.
The Anti-Serotonin Thesis
Serotonin is one of the most mischaracterized molecules in popular neuroscience. Its public identity - the "happy chemical" whose insufficiency causes depression - was always a simplification of the underlying pharmacology, and Peat's critique of serotonin draws on a different and better-supported body of research: the role of serotonin as a vasoconstrictor, as a component of the inflammatory cascade, and as a direct suppressor of mitochondrial function. Peat argued consistently that serotonin behaves as a stress hormone rather than a happiness signal, that its elevation in the context of chronic illness is a response to metabolic suppression rather than a cause of mood disorder, and that reducing serotonin activity - particularly at peripheral tissue - is one of the most effective interventions available for restoring mitochondrial function.
The mechanistic case is worth laying out. Serotonin (5-hydroxytryptamine) is synthesized from tryptophan, both in enterochromaffin cells of the gut (which account for the large majority of total body serotonin) and in raphe nuclei of the brainstem (which produce the centrally acting fraction). In the periphery, elevated serotonin produces vasoconstriction, promotes platelet aggregation, stimulates cortisol release from the adrenal glands, and - via its effects on mitochondrial Complex I - directly impairs the electron transport chain. Peat's framework treats peripheral serotonin elevation as a core feature of chronic metabolic stress: the gut, under conditions of reduced oxidative phosphorylation and increased intestinal bacterial fermentation, overproduces serotonin, which then suppresses the very mitochondrial activity that would relieve the original metabolic stress. The result is a self-reinforcing suppression loop.
The bioenergetic community's tools for reducing serotonin activity include: cyproheptadine (a first-generation antihistamine with potent serotonin receptor antagonist activity), aspirin (which inhibits serotonin release from platelets and reduces prostaglandin-mediated serotonin synthesis), sugar (which raises blood glucose and competes with tryptophan for amino acid transport, reducing brain serotonin synthesis precursor availability), and the broader dietary framework (reducing tryptophan intake via the amino acid composition of the Peat diet). Of these, cyproheptadine is considered the cleanest pharmacological anti-serotonin tool because it acts directly at 5-HT2 receptors without the mechanism-complexity that accompanies SSRIs (which affect reuptake and may paradoxically elevate postsynaptic serotonin exposure at certain receptors). The full compound profile, mechanism research, and dosing context for cyproheptadine in the bioenergetic framework is covered in the cyproheptadine anti-serotonin research guide.
Thyroid Hormone as the Metabolic Keystone
In the bioenergetic framework, thyroid hormone is not one factor among many - it is the master metabolic regulator, and T3 specifically (not T4) is the operationally active thyroid hormone. Peat's writing on this distinction was consistent across decades: T4 is a prohormone, biologically inert until deiodinated to T3; TSH-normal-range medicine routinely misses tissue-level T3 deficiency; and the solution is direct T3 supplementation rather than T4 (levothyroxine), which depends on conversion steps that are frequently impaired in the chronic-illness population. This position is now well-supported by the deiodinase research literature - the documented role of selenium deficiency, inflammation, and cortisol in impairing DIO1 and DIO2 activity means that T4 conversion adequacy cannot be assumed from a normal TSH.
Peat was also specific about T3 pharmacokinetics, and this is where his framework anticipates a practical problem that the bioenergetic research community continues to work through. Immediate-release T3 - Cytomel and its generic equivalents, and the Mexican pharmaceutical analog Cynomel (reviewed in the Cynomel and Cynoplus sourcing and research guide) - produces a sharp serum peak within 1-2 hours of dosing and falls to baseline within 4-6 hours. The spike-and-crash pattern is a recurring concern in the bioenergetic research community Peat helped shape, framed as suboptimal: the brief T3 surge triggers a stress response (elevated heart rate, cortisol pulse), while the subsequent drop leaves the research subject in a trough before the next dose. The ideal, from a bioenergetic standpoint, is continuous T3 availability at a stable serum level - the same availability that endogenous T3 production maintains in healthy thyroid function.
This is the pharmacokinetic rationale for slow-release T3 (SR-T3) as the research-grade reference standard aligned with the Peat framework. SR-T3 formulated in a hydroxypropyl methylcellulose (HPMC) sustained-release matrix delivers T3 over a 4-8 hour window rather than as an immediate bolus. The result is a flat, stable serum curve that avoids the cortisol-stimulating peak of immediate-release T3 while maintaining receptor occupancy throughout the dosing interval - precisely the pharmacokinetic profile Peat's critique of Cytomel was pointing toward. Cyclic T3 protocols, including Wilson's WT3 approach, use sustained-release formulation for this reason. For researchers working within the Peat framework, sustained-release T3 is the compound format that best translates Peat's pharmacokinetic reasoning into practice. The Wilson's SR-T3 Combo Kit is the reference product: SR-T3 in HPMC matrix, formulated specifically for the cyclic T3 protocol context that bioenergetic-framework research favors.
The Pregnenolone-Progesterone-DHEA Stack
Peat's steroid framework begins with pregnenolone - the first steroid synthesized from cholesterol, upstream of all other steroid hormones, and what Peat called the "mother of hormones." In his model, pregnenolone is not merely a precursor to other steroids; it is a neurosteroid with direct effects on GABA and NMDA receptor systems in the central nervous system, and its depletion under conditions of chronic stress is a primary driver of the hormonal imbalances that accompany metabolic suppression. The nervous system synthesizes pregnenolone locally from cholesterol in neuronal mitochondria - a finding documented in the peer-reviewed neurosteroid literature - and this local synthesis is impaired by chronic stress, glucocorticoid excess, and reduced mitochondrial function. The irony Peat emphasized repeatedly: the same mitochondrial impairment that characterizes chronic illness is the impairment that reduces the neurosteroid synthesis capacity needed to recover from it.
Progesterone holds a central position in the bioenergetic framework that extends well beyond its conventional framing as a female reproductive hormone. Peat's case for progesterone - for both male and female research subjects - rested on its role as a mitochondrial protector, an anti-estrogen, an anti-cortisol, and an anti-excitotoxic agent. His early dissertation work established that progesterone promotes oxidative metabolism while estrogen suppresses it; this finding, consistently supported by subsequent cell-biology research, became a pillar of the bioenergetic model. The bioenergetic research community commonly pairs progesterone with thyroid hormone as co-regulators of metabolic rate: T3 sets the metabolic demand, progesterone protects mitochondria from estrogenic and inflammatory suppression, and pregnenolone supports both hormonal synthesis capacity and neurosteroid function simultaneously.
DHEA occupies a distinct but complementary position in the stack. Peat's interest in DHEA was primarily as a mitochondrial metabolic substrate and an antagonist to excess glucocorticoid activity. Elevated cortisol is one of the primary metabolic suppressors in Peat's framework - a direct inhibitor of thyroid hormone conversion and a driver of serotonin release - and DHEA, as the quantitatively dominant adrenal steroid and a functional antagonist to cortisol at the receptor level, provides a natural counterweight. The pregnenolone, progesterone, and DHEA compound profiles - their mechanisms, the research community's approach to dosing context, and how each fits into the full bioenergetic stack - are covered in their own dedicated posts in this cluster.
Methylene Blue and Mitochondrial Cofactors
Methylene blue occupies a unique position in the bioenergetic stack because its mechanism of action is the most directly mitochondrial of any compound Peat endorsed. Where thyroid hormone acts through nuclear receptors to regulate mitochondrial enzyme expression over hours and days, methylene blue acts as an electron shuttle in the mitochondrial electron transport chain itself - accepting electrons from NADH and FADH2 (or from Complex I) and donating them directly to cytochrome c, effectively bypassing Complexes I-III when those complexes are impaired or blocked. This bypass function makes methylene blue a metabolic rescue tool in a way that no hormone can replicate: it maintains ATP synthesis even when the normal electron transport pathway is disrupted by inflammation, oxidative damage, or nitric oxide excess.
The complementarity with T3 is both mechanistic and practical. T3 acts through nuclear thyroid hormone receptors to upregulate the transcription of genes encoding mitochondrial proteins - including the subunits of cytochrome c oxidase (Complex IV), the enzyme at the end of the electron transport chain. Over days to weeks, this genomic action increases the cell's mitochondrial respiration capacity by building more of the machinery. Methylene blue supports the electron transport chain meeting the demand that T3 creates: by shuttling electrons past blocked or insufficient upstream complexes, it ensures that the elevated metabolic activity T3 demands is biochemically achievable even in tissues where the normal electron transport pathway is partially impaired. The two compounds therefore address different temporal scales and different mechanistic levels of mitochondrial function - T3 on the genomic/structural scale, methylene blue on the immediate electron-flow scale. The bioenergetic research community commonly discusses methylene blue as a complementary cofactor rather than a standalone intervention, and the full compound profile, dosing context, and research literature are covered in the dedicated methylene blue post in this cluster.
The Anti-PUFA Argument
Peat's case against polyunsaturated fats (PUFAs) - particularly linoleic acid and other omega-6 fatty acids abundant in vegetable and seed oils - is one of his most contrarian positions and, in light of recent mitochondrial and lipid-biology research, one of his better-supported ones. The core mechanism is straightforward: PUFAs are structurally unstable due to multiple double bonds in their carbon chains, making them highly susceptible to lipid peroxidation - oxidative chain reactions that convert intact fatty acid molecules into reactive aldehyde species (4-HNE, malondialdehyde) that damage proteins, DNA, and membranes. Mitochondrial membranes are particularly vulnerable because they represent some of the highest-flux electron-transfer environments in the cell, generating reactive oxygen species as a byproduct of normal oxidative phosphorylation.
The implications Peat drew from this vulnerability were extensive. PUFA incorporation into mitochondrial membranes - which occurs when dietary PUFAs are consumed and incorporated into membrane phospholipids - increases mitochondrial membrane susceptibility to peroxidative damage, impairs the function of membrane-embedded electron transport complexes, and generates aldehyde products that further suppress mitochondrial enzyme activity. Cardiolipin, the mitochondria-specific phospholipid that is essential for cytochrome c oxidase function, is particularly vulnerable: cardiolipin peroxidation impairs Complex IV activity, reducing ATP synthesis efficiency. This is the mechanistic link Peat drew between dietary PUFA consumption and suppressed metabolic rate - not a dietary preference, but a biochemical chain from fat composition to mitochondrial membrane integrity to oxidative phosphorylation efficiency.
Peat's secondary concern about PUFAs involved estrogenic effects. Multiple animal-model studies have observed that high-PUFA diets promote estrogen synthesis via upregulation of aromatase activity, and that PUFA metabolites (particularly arachidonic acid derivatives) stimulate estrogen production and estrogen receptor activity. Given that the bioenergetic framework treats estrogen excess as a primary metabolic suppressor and progesterone/thyroid deficiency as the primary metabolic restoration pathway, a diet high in compounds that amplify estrogenic signaling is doubly incompatible with the framework's goals. The anti-PUFA argument is therefore not merely about membrane stability but about the hormonal consequences of a chronically high-PUFA diet - consequences that directly antagonize the thyroid and progesterone restoration the protocol is trying to achieve.
The Diet: Fruit, Dairy, Coffee, Coconut Oil, Sugar
The Peat dietary framework is built around substrates that support oxidative phosphorylation and hormonal balance, and it is explicitly contrarian to several dominant currents in contemporary nutrition science. The five central elements are fruit, dairy, coffee, coconut oil, and sugar - a combination that mainstream dietetics would generally classify as high-glycemic, high-saturated-fat, and caffeine-dependent. Peat's rationale for each is mechanistic rather than conventional.
Fruit holds a primary position because of fructose. Peat's case for fructose - long demonized in nutrition science as metabolically harmful - was based on its hepatic glycogenesis properties: fructose is more efficiently converted to liver glycogen than glucose, and maintaining liver glycogen stores is, in Peat's framework, the primary buffer against stress-hormone (cortisol and adrenaline) elevation. When blood sugar falls and liver glycogen is depleted, the stress-hormone response kicks in; liver glycogen maintained by regular fruit consumption keeps the cortisol baseline suppressed. The thyroid-support secondary function of fructose is equally important in the bioenergetic model: adequate liver glycogen is required for efficient T4-to-T3 conversion, because the hepatic enzymes responsible for deiodination are glucose-dependent. Low liver glycogen directly impairs T3 production.
Dairy - primarily milk, cheese, and gelatin - provides the calcium and magnesium framework that Peat considered essential for cellular energy metabolism. Calcium and magnesium together regulate ATP-ase activity, mitochondrial membrane potential, and the calcium-signaling pathways that drive mitochondrial respiration in response to energy demand. Gelatin's glycine content receives specific emphasis in Peat's writing: glycine is anti-excitotoxic, inhibitory at the glycine receptor, and anti-inflammatory via suppression of pro-inflammatory cytokine synthesis. The bioenergetic framework treats glycine as a counter to the excitotoxic and inflammatory drivers of metabolic suppression, and dairy-based gelatin as one of the most accessible dietary sources.
Coffee is Peat's most counterintuitive endorsement from a mainstream-nutrition standpoint. His rationale was not primarily about caffeine's stimulant effects but about coffee's composition: coffee is one of the richest dietary sources of niacin (as niacinamide precursors), it contains antioxidants that reduce lipid peroxidation, and it acutely elevates T3 sensitivity at the cellular level. Caffeine's inhibition of phosphodiesterase (PDE) - raising intracellular cAMP - amplifies the cellular response to thyroid hormone signaling. The bioenergetic community commonly uses coffee as a protocol element to potentiate T3 activity rather than for its stimulant profile.
Coconut oil represents the saturated fat component and the anti-PUFA substitute. Coconut oil is composed predominantly of saturated medium-chain triglycerides (MCTs) - lauric acid, myristic acid, caprylic acid - that lack the double bonds of PUFAs and therefore cannot undergo the lipid peroxidation that impairs mitochondrial membrane function. MCTs also bypass the normal long-chain fatty acid oxidation pathway, entering mitochondria directly without carnitine transport and generating ATP with lower reactive oxygen species production per unit of energy. Sugar - specifically sucrose and the fructose-glucose combination it provides - is defended by Peat on the cortisol-suppression and glycogen-maintenance grounds described above, and on the basis that it provides a clean oxidative substrate without the inflammatory byproducts that accompany excess fat oxidation. The candid acknowledgment the bioenergetic research community must make here: the anti-fat-phobia and pro-sugar elements of the Peat diet are genuinely contrarian within mainstream nutrition science, and the long-term effects of a high-sugar dietary framework in human populations are not well-characterized in controlled research. The theoretical mechanistic reasoning is coherent; the long-term clinical evidence is not settled.
The Controversies (Including the Fasting Debate)
The bioenergetic-research community is not monolithic in its application of Peat's framework, and several of his positions have become active points of debate within the community itself. The most prominent is the fasting debate. Peat was strongly and consistently opposed to intermittent fasting and caloric restriction on cortisol-suppression grounds: fasting raises cortisol, adrenaline, and glucagon; those stress hormones are metabolic suppressors in his framework; and the elevation of these compounds during a fast negates (or reverses) the metabolic benefits that fasting advocates attribute to the practice. Peat also argued that fasting's purported benefits - autophagy induction, mitochondrial biogenesis, insulin sensitivity improvement - were the byproduct of stress-hormone elevation rather than direct metabolic improvement, and that the same benefits could be achieved by thyroid-hormone optimization and the anti-stress dietary framework without the cortisol cost.
A significant and growing subset of bioenergetic researchers now argue that this anti-fasting position, while mechanistically coherent for T3-deficient research subjects, does not hold when T3 is adequately replaced. The argument is specific: the cortisol elevation of fasting is problematic because cortisol suppresses T3 in a T3-deficient state, creating a net metabolic worsening. But a research subject maintaining adequate serum T3 via sustained-release supplementation is, in principle, protected against the T3-suppressing consequence of the cortisol spike. With that protection in place, fasting's autophagy and mitochondrial biogenesis benefits - which are well-documented in the cell-biology and animal-model literature - become available without the metabolic regression that Peat's framework correctly identified for the unsupplemented subject. This is the position developed in detail in the bioenergetic case for strategic fasting, and the T2 angle - specifically how T3+T2 combination protocols alter the fasting-cortisol calculus - is analyzed in the Ray Peat anti-fasting position reconsidered in the context of T2.
Additional controversies that are discussed within the bioenergetic research community include questions about the practical sugar quantities Peat implied (his dietary writing suggested carbohydrate intakes that many researchers find difficult to implement without insulin response concerns), dairy tolerance in the subset of the chronic-illness population with casein sensitivity or lactase deficiency, and coffee dose ceilings (Peat's endorsement of multiple cups per day is practically difficult for research subjects with pre-existing anxiety or adrenal-fatigue presentations, where caffeine can amplify adrenaline). These are not fundamental challenges to the bioenergetic framework's mechanistic coherence - they are implementation complications that practical researchers navigate case by case. The larger question of whether the bioenergetic framework's theoretical foundation is adequately supported by controlled clinical evidence remains open; the research-community consensus is that the mechanistic reasoning is strong and the controlled-trial support is thin, a combination that characterizes much of the advanced thyroid and metabolic research landscape.
Integration with Modern T3→T2 Conversion Research
Peat's thyroid framework was built on T3 as the terminal active thyroid hormone - the molecule that nuclear thyroid hormone receptors (TRalpha and TRbeta) bind and respond to. This framing was consistent with the mainstream endocrinology of Peat's most productive writing decades. What has emerged from the research literature since the foundational 1994 Goglia et al. paper on 3,5-T2 is a refinement of that picture: T3 is not the terminal active thyroid metabolite. The downstream diiodothyronine 3,5-T2 (3,5-diiodothyronine) is a distinct mitochondrially active molecule that bypasses nuclear receptors entirely, acting instead through direct binding to subunit Va of cytochrome c oxidase - the terminal enzyme of the electron transport chain - to acutely elevate aerobic respiration. This mechanism is independent of anything that T3's genomic signaling pathway can accomplish, and its time course is minutes rather than hours.
The T3→T2 conversion problem is therefore a gap in the Peat framework that the bioenergetic research community has only recently begun to address. Peat recognized that T3 conversion from T4 was impaired in chronic illness - this was the correct first insight. He did not address the downstream conversion: T3→T2, which uses the same deiodinase enzyme family (DIO1) and is impaired by the same selenium deficiency and inflammatory cytokine suppression that blocks T4→T3 conversion. A research subject supplementing T3 and relying on endogenous T3→T2 conversion to generate the cytochrome c oxidase-active 3,5-T2 may be producing adequate T3 for nuclear receptor signaling while leaving the mitochondrial pathway that depends specifically on T2 inadequately supported. This explains the T3 protocol plateau - well-described in the research-community literature - where metabolic markers stall despite serum T3 that appears adequate. The full mechanism, the deiodinase dysfunction overlap, and the plateau pattern are analyzed in depth in the T3→T2 conversion problem guide.
The practical extension from the bioenergetic framework is direct. If Peat's foundational insight was to bypass the T4→T3 conversion bottleneck with direct T3 supplementation, the logical next step - one Peat's framework predates - is to bypass the T3→T2 conversion bottleneck by supplementing both T3 and T2 directly. The Wilson's T3+T2 Combo is the research product designed for this combined approach, formulated at a 1:1 T3:T2 ratio in sustained-release capsules. For bioenergetic-framework researchers who have plateaued on T3-alone protocols, the T3+T2 combination represents the updated mechanistic extension of the same deiodinase-bypass logic that Peat's T3 framework established.
The Modified-Peat Position We Take
Chronic-illness.st follows the Peat framework closely on several of its core positions: thyroid hormone is the metabolic keystone, and T3 specifically (not T4) is the relevant compound; serotonin is a stress hormone and anti-serotonin tooling is a legitimate and underutilized metabolic intervention; PUFAs are genuinely damaging to mitochondrial membranes via lipid peroxidation and should be minimized; pregnenolone and progesterone have well-documented mitochondrial-protective and anti-stress functions that merit research attention. These positions are mechanistically coherent, have meaningful peer-reviewed support, and have driven practical protocols that a substantial research community continues to refine and apply.
We depart from Peat's framework in two specific areas. First, on strategic fasting: we argue that fasting is compatible with T3 replacement for research subjects who are maintaining adequate serum T3, and that the autophagy and mitochondrial biogenesis benefits of strategic fasting represent an additive layer to the bioenergetic framework rather than a contradiction of it. Peat's anti-fasting argument is correct for unsupplemented subjects; the T3-supplemented context changes the calculation. Second, we add T2 supplementation as a layer that Peat's framework predates: the 3,5-T2 mitochondrial mechanism documented by Goglia et al. after Peat's most productive writing period represents a genuine mechanistic advance that extends the bioenergetic framework rather than contradicting it. The complete stack that reflects our current research position - combining T3, T2, anti-serotonin tooling, and the Peat dietary framework - is covered in the Ray Peat-aligned thyroid stack post covering T3, T2, and cyproheptadine.
Frequently Asked Questions
What is the Ray Peat protocol?
The Ray Peat protocol - also called the bioenergetic protocol or bioenergetic framework - is a metabolic-optimization approach developed by American endocrinologist and biologist Ray Peat (1936-2022) based on five decades of research into thyroid hormone, steroid hormone, and mitochondrial function. Its core thesis is that metabolism is the master health variable and that T3 (triiodothyronine) is the primary regulator of metabolic rate. The protocol combines direct T3 supplementation, anti-serotonin compounds (principally cyproheptadine), pregnenolone and progesterone as protective steroids, methylene blue as a mitochondrial electron-transport cofactor, and a diet built around fruit, dairy, coffee, coconut oil, and sugar as metabolic-rate-supportive substrates. The protocol is used by a research community focused on chronic illness, metabolic suppression, and thyroid optimization.
Did Ray Peat support T3 over T4?
Yes - consistently and explicitly throughout his writing. Peat argued that T4 (thyroxine or levothyroxine) is a prohormone: biologically inert until deiodinated to T3, and dependent on the DIO1 and DIO2 deiodinase enzymes for that conversion. In the chronic-illness population, those enzymes are commonly impaired by selenium deficiency, systemic inflammation, elevated cortisol, and elevated reverse T3 production - meaning T4 administration does not reliably produce adequate tissue T3. Peat preferred direct T3 supplementation to bypass this conversion bottleneck, and the bioenergetic research community he influenced has long favored sustained-release T3 formulations over the pharmacokinetic spike-and-crash profile of immediate-release Cytomel. This position aligns with the Wilson's WT3 protocol and the broader slow-release T3 research framework.
What is the Ray Peat diet?
The Ray Peat diet is built around foods that support liver glycogen maintenance, reduce cortisol and serotonin, avoid polyunsaturated fat-driven mitochondrial damage, and provide the mineral and substrate foundation for optimal oxidative phosphorylation. The practical framework emphasizes: ripe fruit and fruit juice (fructose for liver glycogen and T3 conversion support), full-fat dairy products and gelatin (calcium, magnesium, glycine), coffee (niacinamide precursors, PDE inhibition, T3 sensitization), coconut oil (saturated MCTs, anti-PUFA substitute), and sugar (cortisol suppression via blood glucose stabilization). The diet explicitly avoids vegetable and seed oils (PUFAs), excess muscle meat (due to high tryptophan content driving serotonin synthesis), and fermented foods (bacterial endotoxin load). Multiple elements of this dietary framework are directly contrarian to mainstream nutritional guidance, including the pro-sugar and high-saturated-fat positions.
Why did Ray Peat oppose serotonin?
Peat's opposition to serotonin was based on its role in peripheral physiology rather than its popular-media image as a mood molecule. In Peat's framework, serotonin is a stress hormone: it produces vasoconstriction, stimulates cortisol release from adrenal tissue, promotes platelet aggregation and the inflammatory cascade, and directly impairs mitochondrial Complex I electron transport. The gut's enterochromaffin cells produce approximately 90 percent of total body serotonin under conditions of reduced oxidative phosphorylation and elevated intestinal bacterial fermentation - creating a feedback loop where metabolic suppression drives serotonin elevation which drives further metabolic suppression. Peat argued that reducing serotonin activity, particularly at the peripheral tissue level, was one of the most direct interventions available for breaking this suppression cycle, and he endorsed cyproheptadine as the most pharmacologically precise tool for doing so.
Did Ray Peat support fasting?
No - Peat was consistently and explicitly opposed to intermittent fasting and caloric restriction. His core argument was that fasting elevates cortisol, adrenaline, and glucagon - stress hormones that suppress T3 at the deiodinase level, promote reverse T3 production, and reduce oxidative phosphorylation capacity. In Peat's framework, the metabolic benefits attributed to fasting (autophagy, insulin sensitivity improvement, mitochondrial biogenesis) are the indirect byproduct of hormetic stress responses rather than direct metabolic improvements, and those same benefits can be achieved by maintaining metabolic rate through thyroid hormone support and the anti-stress dietary framework without the cortisol cost. A growing segment of the bioenergetic research community argues that T3 supplementation neutralizes the primary mechanism of Peat's anti-fasting argument, making strategic fasting compatible with the bioenergetic protocol for adequately T3-supplemented research subjects.
Why does the Ray Peat protocol use pregnenolone and progesterone?
Pregnenolone and progesterone serve different but complementary functions in the bioenergetic stack. Pregnenolone is the cholesterol-derived parent steroid - upstream of all other steroids - and a neurosteroid that the nervous system synthesizes locally in neuronal mitochondria. Peat's framework emphasizes it as a direct mitochondrial support compound and a counter to the neurosteroid depletion that accompanies chronic stress. Progesterone is emphasized for its role as an anti-estrogen and mitochondrial protector: Peat's early dissertation research established that progesterone promotes oxidative metabolism while estrogen suppresses it, and subsequent cell-biology research has supported this distinction at the molecular level. In the bioenergetic community, both compounds are commonly administered alongside T3 as co-regulators of metabolic rate - with T3 setting the metabolic demand and the steroid stack protecting the mitochondrial environment in which that demand is met.
Is the Ray Peat protocol scientifically supported?
The bioenergetic framework has uneven but real support in the peer-reviewed literature. The mechanistic foundations are well-documented: the role of DIO1 and DIO2 deiodinase impairment in T3 deficiency, the anti-inflammatory properties of thyroid hormone, serotonin's peripheral vasoconstrictor and cortisol-stimulating functions, progesterone's neurosteroid and mitochondrial-protective activities, PUFA-driven lipid peroxidation of mitochondrial membranes, and fructose's glycogenesis efficiency are all findings with peer-reviewed support. What is not supported by controlled clinical trials is the integrated protocol as a treatment framework for chronic illness - the specific combination of T3, anti-serotonin compounds, pregnenolone, progesterone, and the Peat diet has not been tested in randomized controlled studies. The framework sits in the category of mechanistically coherent research-community theory: individually supported components, integrated application lacking clinical-trial validation, and outside mainstream endocrinological endorsement.
What is a research-grade T3 source aligned with the Peat framework?
The T3 format most consistent with Peat's pharmacokinetic reasoning is sustained-release T3 (SR-T3) - T3 formulated in a slow-release matrix (typically hydroxypropyl methylcellulose, HPMC) that delivers T3 over a 4-8 hour window rather than as the immediate bolus that Cytomel and Cynomel produce. The bioenergetic research community, reflecting Peat's pharmacokinetic reasoning, has long preferred SR-T3 over immediate-release T3's spike-and-crash profile, and SR-T3's flatter serum curve is the practical implementation of that delivery preference. The Wilson's SR-T3 Combo Kit is the reference product for bioenergetic-framework T3 research, formulated as HPMC sustained-release T3 for cyclic T3 protocol use. For researchers investigating the T3+T2 combination extension that addresses the downstream deiodinase conversion problem Peat's framework predates, the Wilson's T3+T2 Combo provides both T3 and T2 in the same sustained-release format.
Closing Note
The Ray Peat protocol is research-community theory anchored on real mechanism: documented thyroid hormone deiodinase biochemistry, peer-reviewed anti-inflammatory thyroid hormone effects, serotonin's well-characterized peripheral vasoconstrictor and cortisol-stimulating functions, and a mitochondrial PUFA-peroxidation mechanism that is increasingly supported by current lipid-biology research. The framework's integration of T3, anti-serotonin tooling, protective steroids, and a metabolic-substrate diet is not mainstream endocrinology - but its mechanistic coherence has sustained a technically sophisticated research community for over five decades. For researchers investigating this framework, the Wilson's SR-T3 Combo Kit is the thyroid research cornerstone, and the full catalog of bioenergetic-framework research compounds covers the complete stack.